Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET-MR.

IF 4 Q1 CLINICAL NEUROLOGY Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-11-23 eCollection Date: 2024-10-01 DOI:10.1002/dad2.70040

Hossein Moein Taghavi, Mahta Karimpoor, Eric K van Staalduinen, Christina B Young, Marios Georgiadis, Samantha Leventis, Mackenzie Carlson, America Romero, Alexandra Trelle, Hillary Vossler, Maya Yutsis, Jarrett Rosenberg, Guido A Davidzon, Greg Zaharchuk, Kathleen Poston, Anthony D Wagner, Victor W Henderson, Elizabeth Mormino, Michael Zeineh

{"title":"Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET-MR.","authors":"Hossein Moein Taghavi, Mahta Karimpoor, Eric K van Staalduinen, Christina B Young, Marios Georgiadis, Samantha Leventis, Mackenzie Carlson, America Romero, Alexandra Trelle, Hillary Vossler, Maya Yutsis, Jarrett Rosenberg, Guido A Davidzon, Greg Zaharchuk, Kathleen Poston, Anthony D Wagner, Victor W Henderson, Elizabeth Mormino, Michael Zeineh","doi":"10.1002/dad2.70040","DOIUrl":null,"url":null,"abstract":"Introduction: Olfactory dysfunction can be an early sign of Alzheimer's disease (AD). We used tau positron emission tomography-magnetic resonance (PET-MR) to analyze a key region of the olfactory circuit, the piriform cortex, in comparison to the adjacent medial temporal lobe.Methods: Using co-registered magnetic resonance imaging (MRI) and 18F-PI-2620 tau PET-MR scans in 94 older adults, we computed tau uptake in the piriform-periamygdaloid cortex, amygdala, entorhinal-perirhinal cortices, and hippocampus.Results: We found an ordinal cross-sectional increase in piriform cortex tau uptake with increasing disease severity (amyloid-negative controls, amyloid-positive controls, mild cognitive impairment [MCI] and AD), comparable to entorhinal-perirhinal cortex. Amyloid-positive controls showed significantly greater tau uptake than amyloid-negative controls. Negative correlations were present between memory performance and piriform uptake. Piriform uptake was not elevated in cognitively unimpaired Parkinson's disease.Discussion: Cross-sectionally, there is an early increase in tau uptake in the piriform cortex in AD but not in Parkinson's disease.Highlights: Positron emission tomography-magnetic resonance (PET-MR) analysis of the piriform cortex sheds light on its role as a potential early region affected by neurodegenerative disorders underlying olfactory dysfunction.Uptake of tau tracer was elevated in the piriform cortex in Alzheimer's disease (AD) and mild cognitive impairment (MCI) but not in Parkinson's disease (PD).Memory performance was worse with greater piriform uptake.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 4","pages":"e70040"},"PeriodicalIF":4.0000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585164/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Olfactory dysfunction can be an early sign of Alzheimer's disease (AD). We used tau positron emission tomography-magnetic resonance (PET-MR) to analyze a key region of the olfactory circuit, the piriform cortex, in comparison to the adjacent medial temporal lobe.

Methods: Using co-registered magnetic resonance imaging (MRI) and ¹⁸F-PI-2620 tau PET-MR scans in 94 older adults, we computed tau uptake in the piriform-periamygdaloid cortex, amygdala, entorhinal-perirhinal cortices, and hippocampus.

Results: We found an ordinal cross-sectional increase in piriform cortex tau uptake with increasing disease severity (amyloid-negative controls, amyloid-positive controls, mild cognitive impairment [MCI] and AD), comparable to entorhinal-perirhinal cortex. Amyloid-positive controls showed significantly greater tau uptake than amyloid-negative controls. Negative correlations were present between memory performance and piriform uptake. Piriform uptake was not elevated in cognitively unimpaired Parkinson's disease.

Discussion: Cross-sectionally, there is an early increase in tau uptake in the piriform cortex in AD but not in Parkinson's disease.

Highlights: Positron emission tomography-magnetic resonance (PET-MR) analysis of the piriform cortex sheds light on its role as a potential early region affected by neurodegenerative disorders underlying olfactory dysfunction.Uptake of tau tracer was elevated in the piriform cortex in Alzheimer's disease (AD) and mild cognitive impairment (MCI) but not in Parkinson's disease (PD).Memory performance was worse with greater piriform uptake.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用 PET-MR 技术研究阿尔茨海默病（而非帕金森病）梨状皮层中 tau 蛋白的升高。

前言嗅觉功能障碍可能是阿尔茨海默病（AD）的早期征兆。我们利用tau正电子发射断层扫描-磁共振（PET-MR）分析了嗅觉回路的一个关键区域--梨状皮层与邻近的内侧颞叶的对比情况：通过对94名老年人进行磁共振成像（MRI）和18F-PI-2620 tau PET-MR扫描，我们计算了梨状皮层、杏仁核、内侧-边缘皮层和海马的tau摄取量：我们发现，随着疾病严重程度的增加（淀粉样蛋白阴性对照组、淀粉样蛋白阳性对照组、轻度认知功能障碍[MCI]和注意力缺失症），梨状皮层tau摄取量在横断面上呈顺序性增加，与内侧-边缘皮层相当。淀粉样蛋白阳性对照组的tau摄取量明显高于淀粉样蛋白阴性对照组。记忆表现与梨状体摄取量呈负相关。在认知功能未受损的帕金森病患者中，虹膜摄取量没有升高：讨论：从横断面上看，AD患者的梨状皮层中tau摄取早期增加，而帕金森病患者则没有：在阿尔茨海默病（AD）和轻度认知障碍（MCI）患者中，梨状皮层的tau示踪剂摄取量升高，而在帕金森病（PD）患者中则没有升高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.